DOCSLIB.ORG

Salutary Lessons from TGA-Approved Sources for Thyroid-Related Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Salutary Lessons from TGA-Approved Sources for Thyroid-Related Medications REVIEW Barriers in the quest for quality drug information: salutary lessons from TGA-approved sources for thyroid-related medications Jim R Stockigt n iodine-replete countries, about 5% of the population have a ABSTRACT thyroid disorder,1 of whom about a quarter will require long- • term medication either to correct deficiency or to control Product information (PI) for thyroid-related medications I endorsed by the Therapeutic Goods Administration, as thyroid hormone excess. In 2005, about 700 000 Pharmaceutical Benefits Scheme prescriptions were filled in Australia for thyrox- reproduced in the commonly used compilation publications ine, with about 80 000 scripts for the antithyroid drugs carbima- June 2006 MIMS (Monthly index of medical specialties) zole and propylthiouracil.2 annual, MIMS Online and the Australian prescription products Although no major new therapeutic agent has been introduced in guide 2006, was evaluated to see whether it reflects The Medical Journal of Australia ISSN: 0025- contemporary therapeutic practice. the thyroid729X 15 field January for 2007some 186 years, 2 76-79 the body of knowledge and • evidence©The has Medicaladvanced. Journal It is important of Australia that these 2007 developments are Compared with current medical literature, these PI-based reflectedwww.mja.com.au in the product information (PI) widely used by medical sources provide inadequate, inaccurate or outdated practitionersReview and a range of health professionals, who may not refer therapeutic directives. Examples include: directly to current scientific literature on thyroid disorders. MIMS ¾ Incorrect advice that thyroxine therapy should always 3 (Monthly index of medical specialties) annual, in its 30th edition in begin at very low dosage. 2006, and the Australian prescription products guide (APPG) 2006, 4 ¾ Failure to recommend increased thyroxine dosage early 35th edition, are the most commonly used compilations of PI in pregnancy (thus placing the offspring of women being (provided by the drug manufacturer and approved by the Therapeu- treated for hypothyroidism at risk of impaired fetal brain tic Goods Administration [TGA]). Both are mandatory pharmacy development). references specified by some state pharmacy boards.5,6 ¾ Incorrect and potentially unsafe advice to treat My review assesses whether PI-based information on thyroid- thyrotoxicosis with stable iodide in late pregnancy. related medications as reproduced in MIMS annual 2006, MIMS Online and APPG 2006 is in accord with current peer-reviewed ¾ Failure to advise serial adjustment of antithyroid drug medical literature and contemporary therapeutic practice. dosage until after a patient becomes euthyroid (this can result in iatrogenic thyroid dysfunction). Importance of thyroid-related drug information ¾ Outdated advice that antithyroid drugs are not compatible with breastfeeding. There are several reasons why patients taking thyroid-related medications, who number over 200 000 in Australia, need • Recent initiatives to upgrade consumer medicine information reliable information. First, they should aim for some self- (CMI) appear to accept PI-based sources as a reliable sufficiency in relation to their medications, because long-term benchmark for CMI. That inference is not warranted for treatment and follow-up often extends beyond contact with any thyroid-related medications. one medical practitioner. Second, they may need to make • Accountability for the updating of clinical information in PI informed choices between therapeutic alternatives. For example, needs to be defined, and the process for updating PI may a young woman with thyrotoxicosis who has future plans for need to be modified. pregnancy may be offered ablative treatment, with the prospect • Quality drug information, both PI and CMI, depends on of subsequent lifelong thyroxine replacement therapy that will fluent, evidence-based collaboration between suppliers, need to be adjusted during pregnancy. Her alternative of antithy- regulators, prescribers, specialist clinicians and consumers. roid drug treatment, with the possibility of remission or recur- MJA 2007; 186: 76–79 rence, might be dismissed if she were given poorly documented advice about the safety of antithyroid drugs during pregnancy For editorial comment, see page 51 and lactation. Third, there is potential for ill-advised dose adjustment, failure to recognise side effects and, at times, misuse7 MIMS annual states that “Product monographs in MIMS annual of thyroid-related drugs. represent Therapeutic Goods Administration (TGA) approved product information, which is the result of years of research and Sources of drug information development by the sponsor company and of painstaking evalua- The stated aim of the 2006 MIMS annual is to serve as “the tion and review by the Drug Safety and Evaluation Branch of the byword for accurate, reliable, comprehensive and independent TGA”.3 These statements imply an intention to offer both medicines information”. It also states that “Prescribers, and pharmaceutical information and reliable clinical advice. It fol- health care professionals in general, need to be confident in lows that patient care can be influenced by the quality and today’s litigation-conscious environment that the information accuracy of the information in PI supplied by pharmaceutical used as decision support, in both electronic and print formats, is manufacturers or sponsors, and then endorsed by the TGA. This reliable, accurate, from a trusted source AND reflects the current potential link to clinical decisions mandates accountability for APPROVED information”.3 Further, the title page of the 2006 PI-based drug information. 76 MJA • Volume 186 Number 2 • 15 January 2007 Contentious, unsafe, omitted or undocumented recommendations for thyroid-related medications, as reproduced in MIMS and APPG from approved product information (my emphasis indicated by italics) as remission while an antithyroid drug is still required. When control has been THYROXINE achieved, failure to decrease or cease dosage can result in serious iatrogenic Initiation of therapy hypothyroidism (see dose adjustment strategy for propylthiouracil). “In all cases, Oroxine [Sigma] should be initiated at not more than 50 Coordination with radioiodine microgram/day and gradually increased . .” “Neo-Mercazole [Link] should be stopped temporarily at the time of Critique: This absolute restriction, based on caution in initiating thyroxine administration of radioiodine.” therapy in elderly patients with hypothyroidism, may be quite inappropriate. Critique: This recommendation will limit the efficacy of radioiodine. After near-total thyroidectomy in a euthyroid healthy adult, full replacement 8-10,13 Carbimazole needs to be stopped several days before and for several days dosage should be used to avoid unnecessary iatrogenic after radioiodine administration,8,9 to avoid blocking its incorporation into hypothyroidism. For newly diagnosed hypothyroidism in pregnancy, thyroglobulin (the same applies to propylthiouracil). 1.5–2.0μg/kg per day is now recommended as the initial dosage.14 Quality of evidence: Reference 8, 9 (III-3, B). Quality of evidence: Reference 8-10 (III-2, B); 13 (IV, B); 14 (III-3, B). Dose modification in pregnancy PROPYLTHIOURACIL “For women with established hypothyroidism, thyroxine replacement Dose review and modification generally needs to be increased by 25 to 40% during pregnancy, based on “After control of thyrotoxicosis, the dose of propylthiouracil should be measurements of TSH and thyroxine levels at the end of the first and second gradually decreased to 50mg twice daily.” trimesters.” Critique: Dosage of both carbimazole and propylthiouracil needs to be Critique: Dosage does need to be increased, particularly to avoid any reviewed and adjusted before achieving normal hormone levels. Delayed degree of hypothyroidism in the first trimester, when fetal brain development 15 dose adjustment, as advised, can result in severe over-treatment. Dose is critically dependent on maternal thyroxine. Adjustments based on reduction is appropriate when thyroid hormone levels decrease by measurements at the end of the first trimester are likely to be too late to 30%–50%.8,9 address this need.14 Contemporary advice is to optimise the dose of Quality of evidence: Reference 8, 9 (IV, C). thyroxine when pregnancy is anticipated, and to increase dosage by about 30% when pregnancy is confirmed.14 In addition, the statement “clinical Breastfeeding experience does not indicate any adverse effects on the foetus when the “Breastfeeding should be terminated prior to initiation of therapy.” thyroid agents are administered during pregnancy” would be more pertinent Critique: This recommendation was superseded by new data 20 years ago if it emphasised the need to increase dosage early in pregnancy (see comment for carbimazole).16,20,21 Propylthiouracil is often preferred to 14,15 to avoid the adverse effect on the fetus of under-replacement. carbimazole because transfer to milk is less.21 Quality of evidence: Reference 14 (III-3, B); 15 (III-2, B). Quality of evidence: Reference 16, 20, 21 (III-3, B). Indications incompletely documented Inaccurate explanation of mode of action Further indications for the use of thyroxine that have been omitted are: “Propylthiouracil blocks the peripheral conversion of thyroxine (T4) to 1. Thyroxine may be used in conjunction with an antithyroid drug (block– triiodothyronine (T3) by inhibiting incorporation of iodide into tyrosine.” replace regimen)
Load more

Recommended publications
  • Thyroid Hormone Misuse and Abuse
    Endocrine (2019) 66:79–86 https://doi.org/10.1007/s12020-019-02045-1 REVIEW Thyroid hormone misuse and abuse Victor J. Bernet 1,2 Received: 11 June 2019 / Accepted: 2 August 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Thyroid hormone (TH) plays an essential role in human physiology and maintenance of appropriate levels is important for good health. Unfortunately, there are instances in which TH is misused or abused. Such misuse may be intentional such as when individuals take thyroid hormone for unapproved indications like stimulation of weight loss or improved energy. There are instances where healthcare providers prescribe thyroid hormone for controversial or out of date uses and sometimes in supraphysiologic doses. Othertimes, unintentional exposure may occur through supplements or food that unknowingly contain TH. No matter the reason, exposure to exogenous forms of TH places the public at risk for potential adverse side effects. Keywords Thyrotoxicosis ● Thyroid hormone abuse ● Thyroid hormone misuse ● Factitious thyrotoxicosis ● Supplements ● 1234567890();,: 1234567890();,: Analogs Overdose Thyroid hormone misuse and abuse secondary to exogenous TH ingestion that may be unin- tentional or purposeful such as in some cases of Munch- Almost any substance that impacts body physiology and ausen syndrome. Instances of TH misuse can be associated function is at risk for misuse or frank abuse, usually in the with the development of significant side effects. There are misgiven belief that the particular agent whether it be a other instances of chronic, low-grade over treatment with herb, supplement, medication, or hormone has healing TH, which occur for various misreasoning such as weight properties beyond that of which it actually possesses.
    [Show full text]
  • Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate
    2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium.
    [Show full text]
  • EANM Practice Guideline/SNMMI Procedure Standard for RAIU and Thyroid Scintigraphy
    European Journal of Nuclear Medicine and Molecular Imaging (2019) 46:2514–2525 https://doi.org/10.1007/s00259-019-04472-8 GUIDELINES EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy Luca Giovanella 1,2 & Anca M. Avram3 & Ioannis Iakovou4 & Jennifer Kwak5 & Susan A. Lawson3 & Elizabeth Lulaj6 & Markus Luster7 & Arnoldo Piccardo8 & Matthias Schmidt9 & Mark Tulchinsky10 & Frederick A. Verburg7 & Ely Wolin11 Received: 11 July 2019 /Accepted: 29 July 2019 / Published online: 7 August 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Introduction Scintigraphic evaluation of the thyroid gland enables determination of the iodine-123 iodide or the 99mTc-pertechnetate uptake and distribution and remains the most accurate method for the diagnosis and quantification of thyroid autonomy and the detection of ectopic thyroid tissue. In addition, thyroid scintigraphy and radioiodine uptake test are useful to discriminate hyperthyroidism from destructive thyrotoxicosis and iodine-induced hyperthyroidism, respectively. Methods Several radiopharmaceuticals are available to help in differentiating benign from malignant cytologically indeterminate thyroid nodules and for supporting clinical decision-making. This joint practice guideline/procedure standard from the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) provides recommendations based on the available evidence in the literature. Conclusion The purpose of this practice guideline/procedure standard is to assist imaging specialists and clinicians in recommending, performing, and interpreting the results of thyroid scintigraphy (including positron emission tomography) with various radiopharmaceuticals and radioiodine uptake test in patients with different thyroid diseases. Keywords Thyroid . Scintigraphy . Radioiodine uptake test . 99mTc-sestaMIBI, 18F-fluorodeoxyglucose Preamble approval of the Committee on Guidelines and Board of Directors of both organizations.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Ultra-TechneKow FM 2.15-43.00 GBq radionuclide generator 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium pertechnetate (99mTc) injection is produced by means of a (99Mo/99mTc) generator. Technetium (99mTc) decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.01 hours to technetium (99Tc) which, in view of its long half-life of 2.13 x 105 years can be regarded as quasi stable. The radionuclide generator containing the parent isotope 99Mo, adsorbed on a chromatographic column delivers sodium pertechnetate (99mTc) injection in sterile solution. The 99Mo on the column is in equilibrium with the formed daughter isotope 99mTc. The generators are supplied with the following 99Mo activity amounts at activity reference time which deliver the following technetium (99mTc) amounts, assuming a 100% theoretical elution yield and 24 hours time from previous elution and taking into account that branching ratio of 99Mo is about 87%: 99mTc activity (maximum theoretical elutable 1.90 3.81 5.71 7.62 9.53 11.43 15.24 19.05 22.86 26.67 30.48 38.10 GBq activity at ART, 06.00 h CET) 99Mo activity (at ART, 06.00 h 2.15 4.30 6.45 8.60 10.75 12.90 17.20 21.50 25.80 30.10 34.40 43.00 GBq CET) The technetium (99mTc) amounts available by a single elution depend on the real yields of the kind of generator used itself declared by manufacturer and approved by National Competent Authority.
    [Show full text]
  • Thyroid Function Testing and Management During and After Pregnancy Among Women Without Thyroid Disease Before Pregnancy
    RESEARCH HEALTH SERVICES Thyroid function testing and management during and after pregnancy among women without thyroid disease before pregnancy Jennifer M. Yamamoto MD, Amy Metcalfe PhD, Kara A. Nerenberg MD, Rshmi Khurana MD, Alex Chin PhD, Lois E. Donovan MD n Cite as: CMAJ 2020 June 1;192:E596-602. doi: 10.1503/cmaj.191664 ABSTRACT BACKGROUND: Screening in pregnancy between October 2014 and September initiated at a median gestational age of for subclinical hypothyroidism, often 2017. We used delivery records, phys- 7 (interquartile range 5–12) weeks. defined as thyroid-stimulating hormone ician billings, and pharmacy and labora- Among women with first TSH measure- (TSH) greater than 2.5 mIU/L or greater tory administrative data. Our key out- ments of 4.01 to 9.99 mIU/L who were than 4.0 mIU/L, is controversial. We comes were characteristics of TSH not immediately treated, the repeat TSH determined the frequency and distribu- testing and the initiation and continua- measurement was 4.00 mIU/L or below tion of TSH testing by gestational age, tion of thyroid hormone therapy. We in 67.9% of pregnancies. Thyroid hor- as well as TSH values associated with calculated the proportion of pregnan- mone was continued post partum for treatment during pregnancy and the fre- cies with thyroid testing and the fre- 44.6% of the women who started ther- quency of postpartum continuation of quency of each specific thyroid test. apy during their pregnancy. thyroid hormone therapy. RESULTS: Of the 188 490 pregnancies INTERPRETATION: The findings of our METHODS: We performed a retrospec- included, 111 522 (59.2%) had at least study suggest that current practice pat- tive cohort study of pregnancies in 1 TSH measurement.
    [Show full text]
  • CYTOMEL - Liothyronine Sodium Tablet Physicians Total Care, Inc
    CYTOMEL - liothyronine sodium tablet Physicians Total Care, Inc. ---------- Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. DESCRIPTION Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T4, levothyroxine) sodium or triiodothyronine (T3, liothyronine) sodium or both. T4 and T3 are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. T4 contains four iodine atoms and is formed by the coupling of two molecules of diiodotyrosine (DIT). T3 contains three atoms of iodine and is formed by the coupling of one molecule of DIT with one molecule of monoiodotyrosine (MIT). Both hormones are stored in the thyroid colloid as thyroglobulin. Thyroid hormone preparations belong to two categories: (1) natural hormonal preparations derived from animal thyroid, and (2) synthetic preparations. Natural preparations include desiccated thyroid and thyroglobulin. Desiccated thyroid is derived from domesticated animals that are used for food by man (either beef or hog thyroid), and thyroglobulin is derived from thyroid glands of the hog. The United States Pharmacopeia (USP) has standardized the total iodine content of natural preparations. Thyroid USP contains not less than (NLT) 0.17 percent and not more than (NMT) 0.23 percent iodine, and thyroglobulin contains not less than (NLT) 0.7 percent of organically bound iodine.
    [Show full text]
  • Uncommon Causes of Thyrotoxicosis*
    CONTINUING EDUCATION Uncommon Causes of Thyrotoxicosis* Erik S. Mittra1, Ryan D. Niederkohr1, Cesar Rodriguez1, Tarek El-Maghraby2,3, and I. Ross McDougall1 1Division of Nuclear Medicine and Molecular Imaging Program at Stanford, Department of Radiology, Stanford University Hospital and Clinics, Stanford, California; 2Nuclear Medicine, Cairo University, Cairo, Egypt; and 3Nuclear Medicine, Saad Specialist Hospital, Al Khobar, Saudi Arabia Several of the conditions are self-limiting and do not need Apart from the common causes of thyrotoxicosis, such as prolonged treatment. Graves’ disease and functioning nodular goiters, there are When a patient is thought to be thyrotoxic, a convenient more than 20 less common causes of elevated free thyroid hor- algorithm is to measure free thyroxine (free T ) and mones that produce the symptoms and signs of thyrotoxicosis. 4 thyrotropin (TSH). When the former is higher than normal This review describes these rarer conditions and includes 14 il- lustrative patients. Thyrotropin and free thyroxine should be but the latter is suppressed, thyrotoxicosis is diagnosed. measured and, when the latter is normal, the free triiodothyronine When the former is normal but TSH is low, it is valuable to 123 level should be obtained. Measurement of the uptake of Iis measure free triiodothyronine (free T3); when the latter is recommended for most patients. abnormally high, the diagnosis is T3 toxicosis (2–4). When Key Words: thyrotoxicosis; Graves’ disease; thyroiditis; thyroid both free hormones are normal but TSH is low, the term hormones ‘‘subclinical thyrotoxicosis’’ can be applied (5). Once it has J Nucl Med 2008; 49:265–278 been determined that thyrotoxicosis is present, measure- DOI: 10.2967/jnumed.107.041202 ment of 123I uptake can differentiate among several disor- ders (Table 1).
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • A Systematic Review of Drug Therapy for Graves' Hyperthyroidism
    European Journal of Endocrinology (2005) 153 489–498 ISSN 0804-4643 REVIEW A systematic review of drug therapy for Graves’ hyperthyroidism Prakash Abraham, Alison Avenell, Christine M Park, Wendy A Watson and John S Bevan Department of Endocrinology, Health Services Research Unit, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK (Correspondence should be addressed to P Abraham; Email: [email protected]) Abstract We assessed the effects of dose, regimen and duration of anti-thyroid drug therapy for Graves’ thyro- toxicosis on recurrence of hyperthyroidism, course of ophthalmopathy, adverse effects, health-related quality of life and economic outcomes. We undertook a systematic review and meta-analyses of ran- domised controlled trials (RCTs). We identified RCTs regardless of language or publication status by searching six databases, and trial registries. Dual, blinded data abstraction and quality assessment were undertaken. Trials included provided therapy for at least 6 months with follow-up at least 1 year after drug cessation. Fixed or random effects meta-analyses were used to combine study data. Twelve trials compared a Block-Replace regimen (requiring a higher dose of anti-thyroid drug treat- ment) with a Titration regimen. Overall, there was no significant difference between the regimens for relapse of hyperthyroidism (relative risk (RR) ¼ 0.93, 95% confidence interval (CI) 0.84 to 1.03). Par- ticipants were more likely to withdraw due to adverse events with a Block-Replace regimen (RR ¼ 1.89, 95% CI 1.25 to 2.85). Prescribing replacement thyroxine, either with the anti-thyroid drug treatment, or after this was completed, had no significant effect on relapse.
    [Show full text]
  • L-T3) to Levothyroxine (L-T4
    Switching your patient from Liothyronine (L-T3) to Levothyroxine (L-T4)? Answering GP’s frequently asked questions The BTA is aware that some health authorities are advising GPs to switch patients on Liothyronine (L-T3) to Levothyroxine (L-T4). Whilst we appreciate the commercial imperative to cut prescription costs, like you, our first concern is that in all cases the clinical needs of the patient should come before financial considerations. This frequently asked questions (FAQS) sheet has been produced for GPs who are considering switching patients from L-T3 to L-T4. Should my patient be switched from L-T3 to L-T4? The decision to switch from L-T3 to L-T4 should be based on clinical considerations and should be reached in conjunction with the patient after a discussion of the risks and benefits. Patients established on L-T3 who continue to derive benefit from its use should continue on L-T3. However, patients with uncertain benefits should be considered for a switch to L-T4 and advice should be sought from an endocrinologist on how this can be safely done. Is there any problem switching my long established L-T3 patients to L-T4? A change in treatment can result in some instability in thyroid status which can actually cost more to address than continuing with L-T3. The patient should be made aware of this risk to their thyroid status before switching. What is the process for patients who have been advised to switch to L-T4 from combined L-T3 + L-T4 or from L-T3 only? This should be made gradually with the aim of avoiding under-replacement or over- replacement.
    [Show full text]
  • (Armour Thyroid) Treatment in Hypothyroidism
    University of North Dakota UND Scholarly Commons Nursing Capstones Department of Nursing Spring 5-10-2020 Levothryoxine Versus Dessicated Bovine Thyroid (Armour Thyroid) Treatment in Hypothyroidism Christine Zaki [email protected] Follow this and additional works at: https://commons.und.edu/nurs-capstones Recommended Citation Zaki, Christine, "Levothryoxine Versus Dessicated Bovine Thyroid (Armour Thyroid) Treatment in Hypothyroidism" (2020). Nursing Capstones. 318. https://commons.und.edu/nurs-capstones/318 This Independent Study is brought to you for free and open access by the Department of Nursing at UND Scholarly Commons. It has been accepted for inclusion in Nursing Capstones by an authorized administrator of UND Scholarly Commons. For more information, please contact [email protected]. 1 Levothyroxine Versus Desicated Bovine Thyroid (Armour Thyroid) Treatment in Hypothyroidism Christine Zaki The College of Nursing: North Dakota University NURS 997: Family Nurse Practitioner Independent Study Dr. Jackie Roberts May 5, 2020 2 PERMISSION Title: Levothyroxine Verses Desiccated Bovine Thyroid (Armour Thyroid) in The Treatment of Hypothyroidism Department: Nursing Degree : Master of Science In presenting this independent study in partial fulfillment of the requirement for a graduate degree from the University of North Dakota, I agree that the College of Nursing & Professional Disciplines of this University shall make it freely available for inspection. I further agree that permission for extensive copying or electronic access for scholarly purposes may be granted by the professor who supervised my independent study work or, in his/her absence, by the chairperson of the department or the dean of the Graduate School. It is understood that any copying or publication or other use of this independent study or part thereof for financial gain shall not be allowed without my written permission.
    [Show full text]
  • CYTOMEL® Brand of Liothyronine Sodium Tablets
    CYTOMEL® brand of liothyronine sodium tablets DESCRIPTION Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T4, levothyroxine) sodium or triiodothyronine (T3, liothyronine) sodium or both. T4 and T3 are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. T4 contains four iodine atoms and is formed by the coupling of two molecules of diiodotyrosine (DIT). T3 contains three atoms of iodine and is formed by the coupling of one molecule of DIT with one molecule of monoiodotyrosine (MIT). Both hormones are stored in the thyroid colloid as thyroglobulin. Thyroid hormone preparations belong to two categories: (1) natural hormonal preparations derived from animal thyroid, and (2) synthetic preparations. Natural preparations include desiccated thyroid and thyroglobulin. Desiccated thyroid is derived from domesticated animals that are used for food by man (either beef or hog thyroid), and thyroglobulin is derived from thyroid glands of the hog. The United States Pharmacopeia (USP) has standardized the total iodine content of natural preparations. Thyroid USP contains not less than (NLT) 0.17 percent and not more than (NMT) 0.23 percent iodine, and thyroglobulin contains not less than (NLT) 0.7 percent of organically bound iodine. Iodine content is only an indirect indicator of true hormonal biologic activity. Cytomel (liothyronine sodium) Tablets contain liothyronine (L-triiodothyronine or L T3), a synthetic form of a natural thyroid hormone, and is available as the sodium salt. The structural and empirical formulas and molecular weight of liothyronine sodium are given below. 1 Liothyronine Sodium L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt Twenty-five mcg of liothyronine is equivalent to approximately 1 grain of desiccated thyroid or thyroglobulin and 0.1 mg of L-thyroxine.
    [Show full text]